https://youtu.be/iH0a08glQYo Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion
Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster “HER2 Functionalized Nanoparticles Are Safe and Specific for in
Pre-clinical data on Imagion Biosystems’ MagSense HER2+ cancer detection platform have shown: specific binding and detection of HER2+ tumor cells in vitro specific detection of
Imagion Biosystems’ abstract “Detection of HER2+ tumor cells using MagSense® nanoparticles: safety and sensitivity” has been accepted for the 2018 AACR meeting under the organization’s
“Specific Detection of HER-2 positive tumors in mice using superparamagnetic relaxometry” is the title of a poster presented by Erika Vreeland, PhD, at the 2017
This year’s Tech Connect World Innovation Conference featured the poster “Superparamagnetic relaxometry (SPMR) for sensitive detection of HER-2 positive tumors in mice” presented by Imagion
This year’s Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year’s meeting was
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
